Fig. 2: Ibrutinib treatment attenuates CD40-mediated venetoclax resistance. | Leukemia

Fig. 2: Ibrutinib treatment attenuates CD40-mediated venetoclax resistance.

From: Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Fig. 2

A Patient samples obtained at baseline and after two months ibrutinib treatment were unstimulated or cultured on CD40L-expressing 3T3 fibroblasts (3T40), followed by in vitro venetoclax treatment. Viability data were measured by flow cytometry using DiOC6/TO-PRO-3 staining (N = 17). B–E Immunological detection of Bcl-2 family members before and after in vitro CD40 stimulation (3T40) in patient samples at baseline and after ibrutinib treatment (N = 15; BFL-1 N = 7). Two-way ANOVA test was used for statistical analyses.

Back to article page